Cuba Debates Results for Anti-Lung Cancer Vaccine

Havana, Nov 23. -The 4th International Workshop on CIMAvax-EGF, on Wednesday continues sessions in the presence of experts from Peru, Brazil, Argentina, Colombia, France, Belgium, Serbia, Korea and Germany.The meeting, organized by the Molecular Immunology Center and the state-run CIMAB S.A. trade company, analyzes the most recent clinical results with this therapeutic vaccine to treat patients with non-small cell lung cancer.

CIMAvax-EGF is the first vaccine for this kind of cancer in the world, and has been registered in Cuba, Canada, the United States, Japan and South Africa, among other countries, CIMAB S.A. general manager Norkis Arteaga told the press.

Cuba has achieved valuable results with that product, which does not cause severe secondary effects, provokes an immune response, and increases the survival of patients, improving their quality of life.

The meeting takes place at Havana's Palco Hotel. (Prensa Latina)